Shanghai Hengrun Dasson Biotech Secures RMB 200 Million Series B Funding to Advance CAR-T Clinical Trials and IPO Preparation

MedValley News: On September 30, Shanghai Hengrun Dasheng Biotechnology Co., Ltd. (hereinafter referred to as “Hengrun Dasheng”), a cell therapy enterprise based in Zhangjiang Science City, announced the completion of its RMB 200 million Series B financing round. The round was led by Shenzhen Capital Group Co., Ltd. (SCGC), with participation from Yangming Kangyi, Junchenda Capital, Zhanglong Haifa, Shanghai Yongrun, Zeyu Fund, and Qianhai Capital, among others. The funds raised will be used to support the registration clinical trials for three CAR-T product approvals, accelerate the industrialization of CAR-T products, and lay the foundation for subsequent IPO plans.

Currently, Shanghai Hengrun Dasheng Biotechnology Co., Ltd. has obtained three clinical trial approvals for its CAR-T products targeting CD19 and BCMA, which can be used to treat lymphoma, leukemia, multiple myeloma, and other conditions, making it the company with the most CAR-T application approvals for hematologic malignancies in China. Meanwhile, last year, Hengrun Dasheng initiated the construction of a CAR-T GMP manufacturing center covering approximately 11,000 square meters at the Zhangjiang Jinshan Bio-pharmaceutical Base in Shanghai, preparing and laying out for large-scale industrial production.

Dr. Zhou Yi, General Manager of the Healthcare Industry Fund Investment Department at SCGC, stated that Hengrun Dasheng is a leading enterprise in China’s immune cell therapy industry. The company has assembled top-tier R&D teams from both domestic and international markets, boasts a rich product pipeline, and has made rapid progress in registrational clinical trials. This financing will accelerate the industrialization of Hengrun Dasheng’s products. This marks SCGC’s second increased investment in Hengrun Dasheng and the first cell therapy company invested in by the Hongtu Healthcare Industry Fund. SCGC expressed strong expectations for the future development of Hengrun Dasheng.

MedValley Chain

《NMPA Issues China’s Second Clinical Trial Approval for BCMA-Targeted CAR-T Therapy》